Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Beta-cell recovery to counter diabetes

Ziel

Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g. following a strict diet) reducing patient QoL. Even with insulin, less than 20% of patients achieve their target glucose level, which eventually leads to vascular complications (e.g. stroke, renal disease) reducing life expectancy by 10-15 years.
DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels increases.
We expect to out-license our drug to a pharma company, some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026 with the proceeds from Series A to be raised in 2023, which is 80% secured.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2023-ACCELERATOR-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

DIOGENX SAS
Netto-EU-Beitrag
€ 2 500 000,00
Adresse
180 AVENUE DU PRADO
13008 Marseille
Frankreich
KMU
Ja
Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 5 673 000,00